Article Figures & Data
Figures
Tables
Data Supplement
- Supplemental Figures -
Supplemental Figure 1 - Uptake profiles of nine OATP substrates (1 μM) generated in cryopreserved cynomolgus monkey hepatocytes (Lot A: 10310012) in the absence (closed symbols) and presence (open symbols) of OATP inhibitor rifamycin SV (100 μM)
Supplemental Figure 2 - Uptake profiles of nine OATP substrates (1 μM) generated in cryopreserved human hepatocytes (HH1025) in the absence (closed symbols) and presence (open symbols) of OATP inhibitor rifamycin SV (100 μM)
Supplemental Figure 3 - Comparison of CLuptake (panel A), CLactive (panel B), CLpassive (panel C) and Kpuu (panel D) of nine OATP substrates between two different lots (single lot A: 10310012, pooled lot B: 10353012) of cryopreserved cynomolgus monkey hepatocytes
Supplemental Figure 4 - Plasma concentration (ng/mL) over time (h) profiles of nine OATP substrates obtained in cynomolgus monkey
Supplemental Figure 5 - Comparison of in vivo intrinsic hepatic clearance (CLint,h) with scaled in vitro intrinsic clearance (CLint,uptake) of nine OATP substrates in cynomolgus monkey (panel A) and human (panel B) following the optimization of CLint,uptake by the empirical scaling factor from average bias (2.7- and 3.8-fold, respectively)
Supplemental Figure 6 - Correlation between observed and calculated in vivo intrinsic hepatic clearance values CLint,h (mL/min/kg) in humans (panel A-C) and the precision error (as log of the predicted/observed CLint ratio) for predicted human CLint for nine OATP substrates (panel D-E)
- Supplemental Figures -